2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2026. Highlights in this video include: • POTOMAC: Durvalumab + BCG (I+M) improves EFS relative to BCG (I+M) but no difference in OS or PROs in high risk NMIBC • EV302: Enfortumab Vedotin + Pembro maintains PFS, OS, and CR benefit relative to platinum chemotherapy in 1L metastatic Urothelial Carcinoma • NEXUS01: Novel ADC targeting NECTin4 with TOPO1 payload shows promising responses in refractory mUC